KRAS G12	Non Small Cell Lung Cancer	KRAS G12	Non Small Cell Lung Cancer	RMC-6236 Sensitive: C2 – Inclusion Criteria RMC-6236 Sensitive : C2	RMC-6236 Sensitive: C2 – Inclusion Criteria RMC-6236 Sensitive : C2
KRAS G12	Pancreatic Ductal Adenocarcinoma	KRAS G12	Pancreatic Ductal Adenocarcinoma	RMC-6236 Sensitive: C3 – Early Trials RMC-6236 Sensitive : C3	RMC-6236 Sensitive: C3 – Early Trials RMC-6236 Sensitive : C3
KRAS mutation	Pancreatic Ductal Adenocarcinoma	KRAS mutation	Pancreatic Ductal Adenocarcinoma	RMC-6236 Sensitive: D – Preclinical RMC-6236 Sensitive : D	RMC-6236 Sensitive: D – Preclinical RMC-6236 Sensitive : D

daraxonrasib (RMC-6236)

Associations
(3)